IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Peter Bjorquist et al.) Confirmation No. 8143
Application No. 10/578,022) Group Art Unit: 1654
Filed: March 6, 2007) Examiner: Julie Ha
For: Use of Anabaenopeptin-type Peptides for the)
Treatment of a Condition Where Inhibition of Carboxypeptidase U is Beneficial, Novel)
Anabaenopeptin Derivatives and)·
Intermediates Thereof) Date: June 12, 2008

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office Action dated May 12, 2008, the time for responding to which extends through June 12, 2008, Applicants elect without traverse the invention of Group I (*i.e.*, method claims 1, 5, 6, 16, 17 and 22). Compound 1 (as depicted on page 20 of the specification) is elected without traverse as a single disclosed species of formula (I) for examination purposes.

Except for issues payable under 37 C.F.R. 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. 1.16 and 1.17 which may be required, including any required extension of time fees, or to credit any overpayment to Deposit Account 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. 1.136(a)(3).

Dated: June 12 2008

Morgan, Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004

Tel: 202-739-3000 Fax: 202-739-3001 Respectfully submitted,

Morgan, Lewis & Bockius LLP

Robert Smyth

Registration No. 50,801

weer Imy to